{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:22:05Z","timestamp":1792797725961,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001230","name":"Macquarie University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience & Biobehavioral Reviews"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.neubiorev.2022.104706","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T10:57:52Z","timestamp":1653130672000},"page":"104706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"special_numbering":"C","title":["The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955\u20132021) and recommendations for the field"],"prefix":"10.1016","volume":"139","author":[{"given":"Vince","family":"Polito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Liknaitzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neubiorev.2022.104706_bib1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/02770906509106904","article-title":"XXXVIII. Comparison with action of methysergide and psilocybin on test subjects","volume":"3","author":"Abramson","year":"1965","journal-title":"J. Asthma Res."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104706_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/00223980.1955.9712963","article-title":"Lysergic acid diethylamide (Lsd-25): Xi. Content analysis of clinical reactions","volume":"40","author":"Abramson","year":"1955","journal-title":"J. Psychol."},{"key":"10.1016\/j.neubiorev.2022.104706_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/2050324519872284","article-title":"2018: a watershed year for psychedelic science","volume":"5","author":"Aday","year":"2019","journal-title":"Drug Sci., Policy Law"},{"key":"10.1016\/j.neubiorev.2022.104706_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/2050324520974484","article-title":"2019: a year of expansion in psychedelic research, industry, and deregulation","volume":"6","author":"Aday","year":"2020","journal-title":"Drug Sci., Policy Law"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104706_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12954-019-0308-4","article-title":"Psychedelic microdosing benefits and challenges: an empirical codebook","volume":"16","author":"Anderson","year":"2019","journal-title":"Harm Reduct. J."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104706_bib6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00213-018-5106-2","article-title":"Microdosing psychedelics: Personality, mental health, and creativity differences in microdosers","volume":"236","author":"Anderson","year":"2019","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104706_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12954-019-0333-3","article-title":"Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube","volume":"16","author":"Andersson","year":"2019","journal-title":"Harm Reduct. J."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104706_bib8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12954-017-0186-6","article-title":"Psychoactive substances as a last resort\u2014a qualitative study of self-treatment of migraine and cluster headaches","volume":"14","author":"Andersson","year":"2017","journal-title":"Harm Reduct. J."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104706_bib9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cct.2003.10.016","article-title":"Assessment of blinding in clinical trials","volume":"25","author":"Bang","year":"2004","journal-title":"Control. Clin. Trials"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104706_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0022042619871008","article-title":"Accounting for microdosing classic psychedelics","volume":"50","author":"Beaton","year":"2020","journal-title":"J. Drug Issues"},{"issue":"10","key":"10.1016\/j.neubiorev.2022.104706_bib11","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.biopsych.2019.05.019","article-title":"Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers","volume":"86","author":"Bershad","year":"2019","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104706_bib12","first-page":"461","article-title":"Preliminary report on the effects of a low dose of LSD on resting-state amygdala functional connectivity","volume":"5","author":"Bershad","year":"2020","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"issue":"7428","key":"10.1016\/j.neubiorev.2022.104706_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nature11691","article-title":"Automated design of ligands to polypharmacological profiles","volume":"492","author":"Besnard","year":"2012","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104706_bib14","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/02791072.2020.1761573","article-title":"The viability of microdosing psychedelics as a strategy to enhance cognition and well-being\u2014an early review","volume":"52","author":"Bornemann","year":"2020","journal-title":"J. Psychoact. Drugs"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104706_bib15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/00049530.2021.1882266","article-title":"A quantitative exploration of the relationships between regular yoga practice, microdosing psychedelics, wellbeing and personality variables","volume":"73","author":"Bright","year":"2021","journal-title":"Aust. J. Psychol."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104706_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/02791072.2020.1718250","article-title":"Psychedelic microdosing: prevalence and subjective effects","volume":"52","author":"Cameron","year":"2020","journal-title":"J. Psychoact. Drugs"},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104706_bib17","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: past, present, and future","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neubiorev.2022.104706_bib18","series-title":"Systematic Review Software","year":"2021"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104706_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1556\/2054.2021.00157","article-title":"Exploring the relationship between microdosing, personality and emotional insight: a prospective study","volume":"5","author":"Dressler","year":"2021","journal-title":"J. Psychedelic Stud."},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104706_bib20","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/acps.12904","article-title":"Effects of psilocybin therapy on personality structure","volume":"138","author":"Erritzoe","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neubiorev.2022.104706_bib21","series-title":"The Psychedelic Explorer\u2019s Guide: Safe, Therapeutic, and Sacred Journeys","author":"Fadiman","year":"2011"},{"key":"10.1016\/j.neubiorev.2022.104706_bib22","unstructured":"Fadiman, J. (2017). Microdose Research: Without approvals, control groups, double-blinds, staff or funding by Dr James Fadiman. Psychedelic Press, XV. \u3008https:\/\/psychedelicpress.co.uk\/blogs\/psychedelic-press-blog\/microdose-research-james-fadiman\u3009."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104706_bib23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/02791072.2019.1593561","article-title":"Might microdosing psychedelics be safe and beneficial? An initial exploration","volume":"51","author":"Fadiman","year":"2019","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neubiorev.2022.104706_bib24","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00213-019-05417-7","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers","volume":"237","author":"Family","year":"2020","journal-title":"Psychopharmacology"},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104706_bib25","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/BF01919685","article-title":"Hypersensitivity to lysergic acid diethylamide (LSD-25) and psilocybin in essential headache","volume":"30","author":"Fanciullacci","year":"1974","journal-title":"Experientia"},{"key":"10.1016\/j.neubiorev.2022.104706_bib26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jep.2016.05.022","article-title":"Effects of low dose ibogaine on subjective mood state and psychological performance","volume":"189","author":"Forsyth","year":"2016","journal-title":"J. Ethnopharmacol."},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104706_bib27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.neubiorev.2022.104706_bib28","unstructured":"Gleiberman, O., & Gleiberman, O. (2020, March 21). \u2018Dosed\u2019: Film Review. Variety. \u3008https:\/\/variety.com\/2020\/film\/reviews\/dosed-review-1203541242\/\u3009."},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104706_bib29","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/jcph.471","article-title":"Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers: Journal of Clinical Pharmacology","volume":"55","author":"Glue","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.neubiorev.2022.104706_bib30","first-page":"71","article-title":"Pharmacodynamics and therapeutic applications of iboga and ibogaine","volume":"6","author":"Goutarel","year":"1993","journal-title":"Psychedelic Monogr. Essays"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104706_bib31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1001\/archneurpsyc.1958.02340020088016","article-title":"Psychopathology and psychophysiology of minimal LSD-25 dosage: a preliminary dosage-response spectrum","volume":"79","author":"Greiner","year":"1958","journal-title":"A.M.A. Arch. Neurol. Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104706_bib32","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacology"},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104706_bib33","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104706_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0269881117731279","article-title":"Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors","volume":"32","author":"Griffiths","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104706_bib35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0031-6865(97)00014-9","article-title":"Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man","volume":"72","author":"Hasler","year":"1997","journal-title":"Pharm. Acta Helv."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104706_bib36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neubiorev.2022.104706_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104706_bib38","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41386-019-0569-3","article-title":"Distinct acute effects of LSD, MDMA, and d -amphetamine in healthy subjects","volume":"45","author":"Holze","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2022.104706_bib39","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/cpt.2057","article-title":"Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants","volume":"109","author":"Holze","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104706_bib40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pharmthera.2011.03.008","article-title":"Serotonin receptors and heart valve disease \u2013 it was meant 2B","volume":"132","author":"Hutcheson","year":"2011","journal-title":"Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104706_bib41","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/ijnp\/pyz029","article-title":"Motives and side-effects of microdosing with psychedelics among users","volume":"22","author":"Hutten","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neubiorev.2022.104706_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2019.00672","article-title":"Self-rated effectiveness of microdosing with psychedelics for mental and physical health problems amongst microdosers","volume":"10","author":"Hutten","year":"2019","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104706_bib43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.euroneuro.2020.10.002","article-title":"Mood and cognition after administration of low LSD doses in healthy volunteers: a placebo controlled dose-effect finding study","volume":"41","author":"Hutten","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104706_bib44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00408109","article-title":"Comparison of the reactions induced by psilocybin and LSD-25 in man","volume":"1","author":"Isbell","year":"1959","journal-title":"Psychopharmacologia"},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104706_bib45","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/archneurpsyc.1956.02330290012002","article-title":"Studies on lysergic acid diethylamide (LSD-25): 1. Effects in former morphine addicts and development of tolerance during chronic intoxication","volume":"76","author":"Isbell","year":"1956","journal-title":"A.M.A. Arch. Neurol. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104706_bib46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1455072517753339","article-title":"Powerful substances in tiny amounts: an interview study of psychedelic microdosing","volume":"35","author":"Johnstad","year":"2018","journal-title":"Nord. Stud. Alcohol Drugs"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104706_bib47","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/s41598-021-81446-7","article-title":"Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing","volume":"11","author":"Kaertner","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neubiorev.2022.104706_bib48","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320950567","article-title":"The therapeutic potential of microdosing psychedelics in depression","volume":"10","author":"Kuypers","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2022.104706_bib49","series-title":"Modern CNS Drug Discovery: Reinventing the Treatment of Psychiatric and Neurological Disorders","first-page":"257","article-title":"Microdosing psychedelics as a promising new pharmacotherapeutic","author":"Kuypers","year":"2021"},{"key":"10.1016\/j.neubiorev.2022.104706_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/0269881119857204","article-title":"Microdosing psychedelics: More questions than answers? An overview and suggestions for future research","author":"Kuypers","year":"2019","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104706_bib51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/02791072.2019.1683260","article-title":"Psychedelic microdosing: a subreddit analysis","volume":"52","author":"Lea","year":"2020","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neubiorev.2022.104706_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2019.11.008","article-title":"Microdosing psychedelics: motivations, subjective effects and harm reduction","volume":"75","author":"Lea","year":"2020","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.neubiorev.2022.104706_bib53","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00213-020-05477-0","article-title":"Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders","volume":"237","author":"Lea","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neubiorev.2022.104706_bib54","unstructured":"Leonard, A. (2015, November 20). How LSD Microdosing Became the Hot New Business Trip. Rolling Stone. \u3008https:\/\/www.rollingstone.com\/culture\/features\/how-lsd-microdosing-became-the-hot-new-business-trip-20151120\u3009."},{"key":"10.1016\/j.neubiorev.2022.104706_bib55","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bcp.2019.04.013","article-title":"Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use","volume":"164","author":"Luethi","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neubiorev.2022.104706_bib56","article-title":"Plasma psilocin critically determines behavioral and neurobiological effects of psilocybin","author":"Madsen","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104706_bib57","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104706_bib58","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104706_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.54","article-title":"Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects","volume":"7","author":"Mueller","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104706_bib60","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s13063-021-05243-3","article-title":"MDLSD: Study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers","volume":"22","author":"Murphy","year":"2021","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104706_bib61","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1192\/bjp.bp.108.056093","article-title":"Effect of a single dose of citalopram on amygdala response to emotional faces","volume":"194","author":"Murphy","year":"2009","journal-title":"Br. J. Psychiatry"},{"issue":"ja","key":"10.1016\/j.neubiorev.2022.104706_bib62","article-title":"Blinding and expectancy confounds in psychedelic randomised controlled trials","volume":"0","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104706_bib63","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0013-4694(66)90037-X","article-title":"Alterations in the nocturnal sleep cycle resulting from LSD","volume":"21","author":"Muzio","year":"1966","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104706_bib64","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neubiorev.2022.104706_bib65","unstructured":"Nicholson, R. (2018, May 17). The Good Fight: In praise of Diane Lockhart, one of TV\u2019s greatest characters. The Guardian. \u3008http:\/\/www.theguardian.com\/tv-and-radio\/2018\/may\/17\/diane-lockhart-the-good-fight-in-praise-of\u3009."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104706_bib66","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cell.2020.03.020","article-title":"Psychedelic psychiatry\u2019s brave new world","volume":"181","author":"Nutt","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.neubiorev.2022.104706_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2020.09.035","article-title":"Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review","author":"Ona","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neubiorev.2022.104706_bib68","series-title":"The Science of Microdosing Psychedelics","author":"Passie","year":"2019"},{"key":"10.1016\/j.neubiorev.2022.104706_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2020.01681","article-title":"Psychedelic research and the need for transparency: polishing Alice\u2019s looking glass","volume":"11","author":"Petranker","year":"2020","journal-title":"Front. Psychol."},{"key":"10.1016\/j.neubiorev.2022.104706_bib70","article-title":"Microdosing psychedelics: subjective benefits and challenges, substance testing behavior, and the relevance of intention","author":"Petranker","year":"2020","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104706_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211023","article-title":"A systematic study of microdosing psychedelics","volume":"14","author":"Polito","year":"2019","journal-title":"PLOS ONE"},{"issue":"10","key":"10.1016\/j.neubiorev.2022.104706_bib72","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.biopsych.2019.08.021","article-title":"The effects of low doses of lysergic acid diethylamide in healthy humans: demystifying the microdosing of psychedelics","volume":"86","author":"Preller","year":"2019","journal-title":"Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104706_bib73","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1007\/s00213-018-5049-7","article-title":"Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting","volume":"235","author":"Prochazkova","year":"2018","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104706_bib74","doi-asserted-by":"crossref","DOI":"10.1177\/0269881120940937","article-title":"A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers","volume":"35","author":"Ramaekers","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104706_bib75","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/dta.1685","article-title":"Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study","volume":"7","author":"Riba","year":"2015","journal-title":"Drug Test. Anal."},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104706_bib76","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/0269881120908004","article-title":"Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities","volume":"34","author":"Rosenbaum","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2022.104706_bib77","unstructured":"Rosner, A. (2020, January 27). Are Investors Ready To Change Their Minds About Psychedelic Drugs? Forbes. \u3008https:\/\/www.forbes.com\/sites\/abbierosner\/2020\/01\/27\/are-investors-ready-to-change-their-minds-about-psychedelic-drugs\/\u3009."},{"key":"10.1016\/j.neubiorev.2022.104706_bib78","unstructured":"Schroeder, A. (2019, September 6). \u2018It Chapter Two\u2019 misses an opportunity to roast Pennywise. The Daily Dot. \u3008https:\/\/www.dailydot.com\/upstream\/it-chapter-two-movie-review\/\u3009."},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104706_bib79","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1212\/01.wnl.0000219761.05466.43","article-title":"Response of cluster headache to psilocybin and LSD","volume":"66","author":"Sewell","year":"2006","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104706_bib80","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/02791072.1976.10471846","article-title":"DMT & TMA-2","volume":"8","author":"Shulgin","year":"1976","journal-title":"J. Psychedelic Drugs"},{"key":"10.1016\/j.neubiorev.2022.104706_bib81","unstructured":"Siebert, A. (2021). Largest Study Of Psychedelics Shows Benefits Of Microdosing Could Be Placebo Effect. Forbes. \u3008https:\/\/www.forbes.com\/sites\/amandasiebert\/2021\/03\/03\/largest-study-of-psychedelics-shows-benefits-of-microdosing-could-be-placebo-effect\/\u3009."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104706_bib82","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/archpsyc.1994.03950020022002","article-title":"Dose-response study of N,N-dimethyltryptamine in humans. 2. Subjective effects and preliminary-results of a new rating-scale","volume":"51","author":"Strassman","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"issue":"8","key":"10.1016\/j.neubiorev.2022.104706_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012412","article-title":"Psychometric evaluation of the altered states of consciousness rating scale (OAV)","volume":"5","author":"Studerus","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neubiorev.2022.104706_bib84","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.62878","article-title":"Self-blinding citizen science to explore psychedelic microdosing","volume":"10","author":"Szigeti","year":"2021","journal-title":"ELife"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104706_bib85","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/1874473708666150107120930","article-title":"A qualitative report on the subjective experience of intravenous psilocybin administered in an fMRI environment","volume":"7","author":"Turton","year":"2015","journal-title":"Curr. Drug Abus. Rev."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104706_bib86","first-page":"115","article-title":"Effect of threshold doses of LSD on social interaction in healthy students","volume":"14","author":"Vojt\u011bchovsk\u00fd","year":"1972","journal-title":"Act. Nerv. Super."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104706_bib87","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cell.2016.12.033","article-title":"Crystal structure of an LSD-bound human serotonin receptor","volume":"168","author":"Wacker","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104706_bib88","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neulet.2008.02.006","article-title":"Effects of varied doses of psilocybin on time interval reproduction in human subjects","volume":"435","author":"Wackermann","year":"2008","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neubiorev.2022.104706_bib89","series-title":"A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage, and My Life","author":"Waldman","year":"2017"},{"key":"10.1016\/j.neubiorev.2022.104706_bib90","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.drugpo.2019.04.013","article-title":"Narrative identity, rationality, and microdosing classic psychedelics","volume":"70","author":"Webb","year":"2019","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.neubiorev.2022.104706_bib91","unstructured":"Winstock, A.R., Timmerman, C., Davies, E., Maier, L.J., Zhuparris, A., Ferris, J.A., Barratt, M.J., & Kuypers, K.P. C. (2020). Global Drug Survey (GDS) 2020 psychedelics key findings report. \u3008https:\/\/www.globaldrugsurvey.com\/wp-content\/uploads\/2021\/03\/GDS2020-Psychedelics-report.pdf\u3009."},{"key":"10.1016\/j.neubiorev.2022.104706_bib92","unstructured":"Woods, B. (2016, March 2). Can very small doses of LSD make you a better worker? I decided to try it. Vox. \u3008https:\/\/www.vox.com\/2016\/3\/2\/11115974\/lsd-internet-addiction\u3009."},{"key":"10.1016\/j.neubiorev.2022.104706_bib93","article-title":"The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial","author":"Yanakieva","year":"2018","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104706_bib94","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00213-018-5119-x","article-title":"The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial","volume":"236","author":"Yanakieva","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neubiorev.2022.104706_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108071","article-title":"Trends in LSD use among US adults: 2015\u20132018","volume":"212","author":"Yockey","year":"2020","journal-title":"Drug Alcohol Depend."}],"container-title":["Neuroscience & Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763422001956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763422001956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:23:30Z","timestamp":1758968610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763422001956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":95,"alternative-id":["S0149763422001956"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104706","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955\u20132021) and recommendations for the field","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104706"}}